227 related articles for article (PubMed ID: 31782189)
1. Cutaneous thrombosis associated with eltrombopag treatment for immune thrombocytopenia.
Iinuma S; Nagasawa Y; Sasaki K; Hayashi K; Kanno K; Honma M; Sugawara M; Kinouchi M; Obata M; Ishida-Yamamoto A
J Dermatol; 2020 Feb; 47(2):e57-e58. PubMed ID: 31782189
[No Abstract] [Full Text] [Related]
2. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Panzer S; Pabinger I
Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
[No Abstract] [Full Text] [Related]
3. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Mulla CM; Rashidi A; Levitov AB
Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
[No Abstract] [Full Text] [Related]
4. Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.
Gunes H; Kivrak T
Curr Drug Saf; 2016; 11(2):174-6. PubMed ID: 26560493
[TBL] [Abstract][Full Text] [Related]
5. Severe cutaneous toxicity related to Eltrombopag.
Meyer SC; Rovó A; Tsakiris DA; Scherer K; Tichelli A; Holbro A
Br J Haematol; 2013 Feb; 160(3):412-4. PubMed ID: 23151239
[No Abstract] [Full Text] [Related]
6. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.
Lambert MP; Witmer CM; Kwiatkowski JL
Am J Hematol; 2017 Jun; 92(6):E88-E91. PubMed ID: 28240793
[No Abstract] [Full Text] [Related]
7. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
Wang X; Liu X; Wang L; Wang JY; Li A
Blood Coagul Fibrinolysis; 2019 Mar; 30(2):71-74. PubMed ID: 30720490
[TBL] [Abstract][Full Text] [Related]
8. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
9. Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient.
Andic N; Gunduz E; Akay OM; Şahin D; Teke HÜ
Platelets; 2014; 25(1):69-70. PubMed ID: 23320868
[TBL] [Abstract][Full Text] [Related]
10. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
11. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
12. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Scully M; Kaczmarski R; Myers B; Collins R; Emohare O; Bolton-Maggs PH
Br J Haematol; 2012 Apr; 157(2):259-60. PubMed ID: 22091659
[No Abstract] [Full Text] [Related]
16. Thrombosis of a Left Atrial Appendage Occluder After Treatment With Thrombopoietin Receptor Agonists.
Cubero-Gallego H; Romaguera R; Teruel L; Gomez-Lara J; Berdejo J; Gomez-Hospital JA; Cequier A
JACC Cardiovasc Interv; 2018 Jan; 11(2):e15-e16. PubMed ID: 29289629
[No Abstract] [Full Text] [Related]
17. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study.
Cheng X; Yan K; Ma J; Chen Z; Zhao L; Wang X; Wu R
Int J Immunopathol Pharmacol; 2019; 33():2058738419872120. PubMed ID: 31438744
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag for use in children with immune thrombocytopenia.
Kim TO; Despotovic J; Lambert MP
Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
[TBL] [Abstract][Full Text] [Related]
20. Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag.
Sperati CJ; Streiff MB
Am J Hematol; 2010 Sep; 85(9):724-6. PubMed ID: 20652968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
